Cardiovascular Clinical Trials

Statistical methods in cardiovascular trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All cardiovascular trials

965 results

• PEFCATIIIndependent statistical analysis of PEFCATII Expanded Safety and Feasibility Study of the FARAPULSE Endocardial Multi Ablation System to Treat Paroxysmal Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 10NCT04170608
• Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7): Complete Statistical AnalysisIndependent statistical analysis of Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 244NCT00732641
• Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 3NCT05191472
• Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 13NCT03506360
• Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 50NCT00546377
• Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD: Complete Statistical AnalysisIndependent statistical analysis of Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04458103).Phase NAResults postedn = 161NCT04458103
• Performance of Masimo INVSENSOR00057 in Detecting Atrial Fibrillation (Afib): Complete Statistical AnalysisIndependent statistical analysis of Performance of Masimo INVSENSOR00057 in Detecting Atrial Fibrillation (Afib): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05472012).Phase NAResults postedn = 139NCT05472012
• PERFUSEIndependent statistical analysis of Multicenter, Nonrandomized, Prospective Study of Pulmonary Embolism Removal With the AngioJet 6F Ultra System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 7NCT01638468
• Perioperative Blood Pressures and Chronic Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Perioperative Blood Pressures and Chronic Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02136810).Phase NAResults postedn = 200NCT02136810
• Peripheral Nerve Blocks for Above-the-knee Amputations: Complete Statistical AnalysisIndependent statistical analysis of Peripheral Nerve Blocks for Above-the-knee Amputations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03404180).Phase 4Results postedn = 30NCT03404180
• PERSIST-AVRIndependent statistical analysis of Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02673697).Phase NAResults postedn = 914NCT02673697
• Personalized Warfarin Dosing by Genomics and Computational Intelligence: Complete Statistical AnalysisIndependent statistical analysis of Personalized Warfarin Dosing by Genomics and Computational Intelligence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00872079).Phase NAResults postedn = 175NCT00872079
• PEVARIndependent statistical analysis of Percutaneous Endovascular Aneurysm Repair (PEVAR) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01070069).Phase NAResults postedn = 192NCT01070069
• Pharmacokinetic Study of Intranasal Dexmedetomidine in Pediatric Patients With Congenital Heart Disease: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic Study of Intranasal Dexmedetomidine in Pediatric Patients With Congenital Heart Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1Results postedn = 28NCT03417999
• Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 12NCT02256345
• Pharmacological Effects of Crushing Prasugrel in STEMI Patients: Complete Statistical AnalysisIndependent statistical analysis of Pharmacological Effects of Crushing Prasugrel in STEMI Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02212028).Phase 4Results postedn = 52NCT02212028
• Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 53NCT02145403
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 184NCT00531284
• Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 65NCT01832727
• Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 32NCT02331368
• Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 36NCT00423592
• Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00530816).Phase 2Results postedn = 164NCT00530816
• Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 286NCT03070782
• Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy: primary endpoint results, effect estimate…Phase 2Results postedn = 57NCT04140162
• Phase I Study of OPC-61815: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of OPC-61815: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03510663).Phase 1Results postedn = 48NCT03510663
• Physical Health in Midlife: Influences of Adversity and Relationships Over Time: Complete Statistical AnalysisIndependent statistical analysis of Physical Health in Midlife: Influences of Adversity and Relationships Over Time: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 210NCT01853332
• Physician-Sponsored IDE for Talent Endoluminal Spring Graft System in Patients With Abdominal Aortic Aneurysms (AAA): Complete Statistical AnalysisIndependent statistical analysis of Physician-Sponsored IDE for Talent Endoluminal Spring Graft System in Patients With Abdominal Aortic Aneurysms (AAA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 49NCT00695253
• Physiologic Effect of Topical Nitroglycerin on Microcirculation Capacity in Patients With Circulatory Shock.: Complete Statistical AnalysisIndependent statistical analysis of Physiologic Effect of Topical Nitroglycerin on Microcirculation Capacity in Patients With Circulatory Shock.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 44NCT05102734
• Physiologic Pacing Registry: Complete Statistical AnalysisIndependent statistical analysis of Physiologic Pacing Registry: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03719040).Phase NAResults postedn = 870NCT03719040
• PII S3i CAPIndependent statistical analysis of PARTNER II Trial: S3iCAP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02687035).Phase NAResults postedn = 1,822NCT02687035
• Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 14NCT01529502
• Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 2NCT00607477
• PilotNR-LVADIndependent statistical analysis of Nicotinamide Riboside in LVAD Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03727646).Phase EARLY_1Results postedn = 5NCT03727646
• PIONEER 6Independent statistical analysis of PIONEER 6, the randomized phase 3 trial of oral semaglutide versus placebo in subjects with type 2 diabetes, including its MACE endpoint, non-inferiority analysis, Cox model, hazard ratio,…Phase 3Results postedn = 3,183NCT02692716
• PIONEER AF-PCIIndependent statistical analysis of A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention: primary endpoint…Phase 3Results postedn = 2,124NCT01830543
• PLANETIndependent statistical analysis of Aflibercept in Polypoidal Choroidal Vasculopathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02120950).Phase 4Results postedn = 333NCT02120950
• Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT): Complete Statistical AnalysisIndependent statistical analysis of Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 16NCT01518153
• PLATINUM QCAIndependent statistical analysis of A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 100NCT00824434
• Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies: primary endpoint results,…Phase NAResults postedn = 1NCT01076270
• PLUSIndependent statistical analysis of Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 290NCT01464307
• POC1Independent statistical analysis of Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 30NCT00511875
• POINTIndependent statistical analysis of Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 4,881NCT00991029
• POLBOS-LMIndependent statistical analysis of POLish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 130NCT03508219
• PolypillIndependent statistical analysis of Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 475NCT00603590
• Portico and Navitor India Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of Portico and Navitor India Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05171712).Phase NAResults postedn = 30NCT05171712
• PORTICO-1Independent statistical analysis of 5 Year Observation of Patients With PORTICO Valves: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01802788).Phase NAResults postedn = 1,032NCT01802788
• POSITIVE Stroke Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of POSITIVE Stroke Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01852201).Phase NAResults postedn = 33NCT01852201
• Post-Approval Study Protocol of the St. Jude Medical Trifecta Valve: Complete Statistical AnalysisIndependent statistical analysis of Post-Approval Study Protocol of the St. Jude Medical Trifecta Valve: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01514162).Phase NAResults postedn = 245NCT01514162
• Post-Market Surveillance With a Novel mHealth Platform: Complete Statistical AnalysisIndependent statistical analysis of Post-Market Surveillance With a Novel mHealth Platform: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03436082).Phase NAResults postedn = 60NCT03436082
• POST-OP PilotIndependent statistical analysis of Pilot Study of Atorvastatin for Orthopedic Surgery Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02197065).Phase 2Results postedn = 20NCT02197065

← All therapeutic areas